Literature DB >> 23743990

Lupus anticoagulant, warfarin, and alternative laboratory monitoring of anticoagulation.

Siva S Ketha1, Rajiv K Pruthi, Robert D McBane, Waldemar E Wysokinski.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 23743990     DOI： 10.1007/s11239-013-0949-1

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  10 in total

1.  Effect of lupus anticoagulants on INR with different thromboplastins.

Authors:  A S Lawrie; I J Mackie; G Purdy; S J Machin
Journal:  Blood Coagul Fibrinolysis       Date:  2001-04       Impact factor: 1.276

2.  A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome.

Authors:  Mark A Crowther; Jeff S Ginsberg; Jim Julian; Judah Denburg; Jack Hirsh; James Douketis; Carl Laskin; Paul Fortin; David Anderson; Clive Kearon; Ann Clarke; William Geerts; Melissa Forgie; David Green; Lorrie Costantini; Wendy Yacura; Sarah Wilson; Michael Gent; Michael J Kovacs
Journal:  N Engl J Med       Date:  2003-09-18       Impact factor: 91.245

3.  Three-stage chromogenic assay for the analysis of activation properties of factor X by cancer procoagulant.

Authors:  W P Mielicki; S G Gordon
Journal:  Blood Coagul Fibrinolysis       Date:  1993-06       Impact factor: 1.276

4.  Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins.

Authors:  A Tripodi; V Chantarangkul; M Clerici; B Negri; M Galli; P M Mannucci
Journal:  Br J Haematol       Date:  2001-12       Impact factor: 6.998

5.  A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS).

Authors:  G Finazzi; R Marchioli; V Brancaccio; P Schinco; F Wisloff; J Musial; F Baudo; M Berrettini; S Testa; A D'Angelo; G Tognoni; T Barbui
Journal:  J Thromb Haemost       Date:  2005-05       Impact factor: 5.824

6.  Falsely elevated INRs in warfarin-treated patients with the lupus anticoagulant.

Authors:  M J Sanfelippo; J Sennet; E J McMahon
Journal:  WMJ       Date:  2000-06

7.  Monitoring warfarin therapy in patients with lupus anticoagulants.

Authors:  S Moll; T L Ortel
Journal:  Ann Intern Med       Date:  1997-08-01       Impact factor: 25.391

8.  Control of oral anticoagulation in patients with the antiphospholipid syndrome--influence of the lupus anticoagulant on International Normalized Ratio. Groupe Méthodologie en Hémostase du Groupe d'Etudes sur l'Hémostases et la Thrombose.

Authors:  A Robert; A Le Querrec; B Delahousse; C Caron; L Houbouyan; B Boutière; M H Horellou; G Reber; P Sié
Journal:  Thromb Haemost       Date:  1998-07       Impact factor: 5.249

9.  Unreliability of international normalized ratio for monitoring warfarin therapy in patients with lupus anticoagulant.

Authors:  Terry K Rosborough; Michele F Shepherd
Journal:  Pharmacotherapy       Date:  2004-07       Impact factor: 4.705

10.  The international normalized ratio (INR) for monitoring warfarin therapy: reliability and relation to other monitoring methods.

Authors:  D T Le; R T Weibert; B K Sevilla; K J Donnelly; S I Rapaport
Journal:  Ann Intern Med       Date:  1994-04-01       Impact factor: 25.391
  10 in total
  1 in total

1.  Variability in the international normalised ratio (INR) in patients with antiphospholipid syndrome and positive lupus anticoagulant: should the INR targets be higher?

Authors:  Marielena Baquero-Salamanca; Angélica María Téllez-Arévalo; Carlos Calderon-Ospina
Journal:  BMJ Case Rep       Date:  2015-04-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.